Wei Zhang, MD, PhD

Professional Background

Wei Zhang, MD, PhD, FCAP, is a board-certified AP/CP-trained pathologist, who serves as the Medical Director of Molecular Pathology (Solid Tumor) at the University of Kansas Medical Center (KUMC). Dr. Zhang holds the academic title of Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Kansas School of Medicine. She completed her doctoral training in Japan, followed by residency in pathology, and subspecialty fellowship training in gastrointestinal and liver pathology in Motefiore Medical Center and molecular genetic pathology in Mount Sinai Health System in New York. Dr. Zhang's clinical expertise encompasses gastrointestinal and hepatopathology, solid tumor molecular diagnostics, and precision biomarker testing. In addition to her diagnostic responsibilities, she serves as Chair of the Precision Medicine Conference at KUMC, and is an active member of the College of American Pathologists Personalized Health Care Committee and the Association for Molecular Pathology Economic Affairs Committee. She is actively engaged in clinical research, medical education, and national and international scientific presentations, with a focus on advancing precision oncology and molecular pathology practice.

• BM, Medicine, China Medical University, Shenyang, Liaoning
• PhD, Molecular Biology, Ehime University School of Medicine, Toon, Ehime
• Residency, Pathology (AP/CP), The Mount Sinai Health System, New York, NY
• Residency, Chief Resident, Pathology (AP/CP), The Mount Sinai Health System, New York, NY
• Clinical Fellowship, GI/Liver Pathology, The Montefiore Medical Center/Albert Einstein Medical College, Bronx, New York
• Clinical Fellowship, Molecular Genetic Pathology, The Mount Sinai Health System, New York, NY

Research

Overview

Dr. Zhang is actively engaged in the diagnostic surgical and molecular genetic pathology service and has special clinical interests in solid tumor genetics. Dr. Zhang's major research interests focus on the pathogenesis and treatment of liver, colorectal, and anal cancers. She is also interested in biomarker discovery and development of new molecular diagnostic assays.

• Zhang W, Acuna-Villaorduna A, Kuan K, Gupta S, Hu S, Ohaegbulam K, Albanese J, Kaumaya M, Levy R, Hwang RR, Zang X, Lin J, Liu Q, Maitra R, Goel S. 2021. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.. Clinical colorectal cancer, 20 (2), 161-169. https://pubmed.ncbi.nlm.nih.gov/33745842/
• Zhang W, Yao J, Zhong M, Zhang Y, Guo X, Wang HY. 2021. A Brief Overview and Update on Major Molecular Genomic Alterations in Solid, Bone and Soft Tissue Tumors, and Hematopoietic As Well As Lymphoid Malignancies.. Archives of pathology & laboratory medicine, 145 (11), 1358-1366. https://pubmed.ncbi.nlm.nih.gov/34270703/
• Gunder LC, Moyer TH, Johnson HR, Auyeung AS, Leverson GE, Zhang W, Matkowskyj KA, Carchman EH. 2023. Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.. The Journal of surgical research, 282, 137-146. https://pubmed.ncbi.nlm.nih.gov/36274448/